Gilead Sciences’ Post

#News for #Investors and #Media: We’re unveiling our breast cancer pipeline at #SABCS24 this week, sharing early data for our investigational CDK4 inhibitor and showcasing our commitment to developing new and innovative medicines to advance standards of care for patients with breast cancer. Read more about our research at https://ow.ly/4BFS50UpKWf  #BreastCancer 

Today is #WorldPancreaticCancer Day. Catch up on the latest treatment breakthroughs and guidance, including strategies for managing resectable pancreatic cancer and metastatic pancreas cancer. Watch the full session here: https://ow.ly/rKOU50U72T1 #MedOnc #CancerCare #PancreaticCancer

#ESMO2024 is about to start! Once more, another chance to discuss about #research and groundbreaking #treatments, generate insights, and reassure our #commitment to bring #innovation to #patients Let’s connect, learn, discuss, and continue working tirelessly to bend survival curves. Ping me if you are around and interested on learning about us!

Pancreatic cancer screenings hold great promise in detecting the disease at an earlier, more treatable stage. Learn more about what the screenings consist of and when you should consider speaking with your doctor. And for more information on pancreatic cancer screenings at CentraState: https://lnkd.in/exVu6s-s #PancreaticCancer #CanerScreenings

The October issue of TPharm is now live! Considered the “Father of Tamoxifen,” for #BreastCancerAwarenessMonth, we're honoring the life of Dr. V. Craig Jordan for his significant contributions to breast cancer treatment. Hear from his colleagues and students about his dedication and leadership in the fight to treat breast cancer. Read the issue here: https://bit.ly/48bkVrN. #pharmacology

We're excited to share MSHO member, BeiGene's FDA approval for TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1). https://ow.ly/411350UxfEq #MSHO25 #FDAapproved #StomachCancer

It's not too late to register for this week's webinar, Oncology 2050: Have We Been Thinking About the Management of Cancer in the Right Way? Join us as we dive into the future of oncology, redefining treatment strategies, advancing AI, and more. Register at https://lnkd.in/gRc_wcPh Hear from our panel of experts, including Axel Hoos, Peter Sandor, EVP, Astellas Pharma US, and Lumanity's Jeff Bockman, Viraj Parekh, and Dennis Chang. #Oncology #Cancer #CancerProgress #CancerTreatment #AIinCancerTreatment

Exciting news from the U.S. Food and Drug Administration (FDA) today in approving TEVIMBRA in the U.S. for first-line treatment of gastric and gastroesophageal junction cancers in combination with chemotherapy. BeiGene #patientfirst #fdaapproval

#News for #Investors and #Media: Today we announced the U.S. FDA has approved our PD-1 inhibitor, in combination with chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (≥1). Gastric cancer is the world’s 5th most common cancer, and in the U.S. approximately 27,000 patients are diagnosed each year. This approval marks a significant step forward in our mission to deliver transformative therapies to patients with cancer. #stomachcancer https://ow.ly/411350UxfEq

Great news today, fostrox has received IND approval by FDA to be evaluated in combination with Lenvima. Another important step on our ambitious journey to make fostrox the first, approved treatment option for second-line advanced liver cancer patients who have previously been treated with immunotherapy combination. Link to the press release in comment below.